Vyome Holdings has published the results of a preclinical study on its uveitis candidate VT‑1908 in the peer‑reviewed Journal of Ophthalmic Inflammation and Infection, a Springer‑Nature journal. The study shows that topical eye drops of VT‑1908 achieve therapeutic drug concentrations in the eye without irritation or toxicity, and reduce uveitis scores and lymphocyte counts in the anterior chamber to a degree comparable with topical prednisone.
The data address a critical unmet need in uveitis treatment. Uveitis accounts for 10‑15% of blindness cases in developed nations and is responsible for approximately 30,000 new cases of legal blindness each year in the United States. The U.S. market for uveitis therapies is projected to reach $3 billion by 2032, while the broader global ocular inflammation market is expected to exceed $20 billion by 2030.
Vyome’s dual‑action rational therapeutics platform is designed to deliver non‑steroidal topical therapies, and the positive preclinical results for VT‑1908 reinforce the company’s strategy to replace steroid‑based eye drops with a safer alternative. The company plans to initiate a Phase 1/2 clinical trial of VT‑1908 in the second half of 2026, leveraging its India innovation corridor to keep development costs low and accelerate human data generation.
"There remains a significant unmet need for safe and effective topically administered therapies to replace topical steroid use in the treatment of ocular inflammation. While steroids are widely used, they are associated with well‑documented complications. The fact that VT‑1908 was as effective as a steroid in the uveitis preclinical model and shows a very good safety profile supports its potential as an effective alternative to steroids in the eye," said Dr. Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and co‑founder of Vyome.
"The broader addressable global market to treat inflammation in the eye is expected to exceed $20B by 2030. Based on our pre‑clinical findings, we intend to leverage the India innovation corridor to advance VT‑1908 into clinical development in a very capital‑efficient manner, to generate human clinical data that could result in a significant value inflection," added Venkat Nelabhotla, CEO of Vyome.
The company has been actively raising capital, including through an ATM facility, to fund its development programs and extend its cash runway, underscoring its commitment to bringing VT‑1908 to market while managing financial risk.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.